Obesity has become a central issue in the global health care agenda; both governments and their citizens are becoming increasingly more conscious about this problem, which is having strong negative consequences in terms of personal well-being and public health care costs. Recognizing the problem is the first step toward improvement, but we still have a long way to go in order to find permanent solutions to the global obesity epidemic.
The war against obesity is here to stay, and it will provide different opportunities for companies and their shareholders to profit from this trend over years to come.
The obesity pandemic
According to the latest annual report from the Robert Wood Johnson Foundation and the Trust for America's Health, adult obesity rates have remained level in almost every state in the U.S. over the last years. But overweight and obesity rates are still too high: More than two-thirds of American adults are either overweight or obese, 13 states have adult obesity rates above 30%, 41 states have rates above 25%, and every state is above 20%.
Obesity is not only associated with developed countries anymore. According to a recent report by the United Nations Food and Agricultural Organization, Mexico has surpassed the US as the most obese nation in the world with a 32.8% obesity rate among Mexican adults, compared to 31.8% among adults in the United States.
More sedentary urban jobs, coupled with a higher concentration of commercially available low-quality food and poor nutritional education are expanding the obesity epidemic in emerging countries.
Diabetes, asthma, orthopedic problems, and some types of cancer are directly related to obesity, so this has huge implications on a personal level and also when it comes to public health care costs. The world is at war against obesity, and plenty of resources will be invested in that battle over the next years.
The obesity pills
Two biotech companies are fighting for the leading position when it comes to commercializing drugs to combat obesity: Arena Pharmaceuticals (NASDAQ:ARNA) with Belviq and VIVUS (NASDAQ:VVUS) with Qsymia -- both drugs are already competing against each other in the market -- and investors have some strong reasons to closely monitor the evolution of sales.
Arena and VIVUS are relatively small companies with market capitalizations in the area of $1.54 billion and $1.23 billion, respectively. Considering the size of the opportunity, if any of them manages to achieve considerable success, investors could be rewarded with explosive returns in the middle term.
On the other hand, these companies expose investors to significant risks -- developing and marketing new drugs is always an expensive and uncertain activity -- and Arena nor VIVUS has proven the commercial success of their respective drugs. Sales of Belviq and Qsymia have been lackluster so far, and it's far too early to make any definitive assessments, so both obesity drugs are facing significant challenges.
When it comes to treating obesity, diet and exercise is still the preferred recommendation by doctors around the world, and any drug would need to prove strong efficacy and low side effect risks if it's going to change that. Both Arena and VIVUS are trying to improve insurance coverage for their drugs, and that's an important factor to watch as it could have important implications on the positive or negative side depending on the extent of coverage they manage to obtain.
Fortunately, not every bet on the war against obesity is necessarily a high-risk investment. Companies like Whole Foods. (NASDAQ:WFM) and Nike (NYSE:NKE) provide the chance to benefit from the trend toward healthier living habits while at the same time positioning your portfolio in high-quality businesses with rock-solid fundamentals.
Whole Foods enjoys a leadership position in the organic and natural foods industry, and the company is also one of the best managed grocery retailers in the U.S. with profit margins substantially above those of the competition.
Whole Foods has been remarkably successful in riding the healthy eating trend over the last years, and the company still has plenty of opportunities for expansion both in the U.S. and abroad. Management is forecasting sales growth in the range of 12% to 14% for 2014 on the back of 6.5%-8% comparable store sales growth and 8%-9% square footage expansion, so momentum is still strong for this organic food leader.
Nike is a global powerhouse in the athletic footwear and apparel business, and the company owns the most recognized brand in the industry, which allows it to obtain superior pricing power and above-average profitability for shareholders. Product innovation, powerful marketing campaigns, and a wide distribution network have been the company's success drivers over the last decades.
The company reported a 7% increase in revenues from continuing operations in the last quarter, and sales excluding currency charges grew at a 9% versus the same quarter in the previous year. Future orders were up 8% in the quarter, so Nike is performing strongly and is well positioned to continue benefiting from healthier living habits around the world.
There are different approaches to investing in the war against obesity. Biotech companies like VIVUS and Arena offer explosive upside potential if they manage to succeed with their obesity drugs, but the risks can be too high for many investors. These are high-risk, high-reward situations.
Companies like Nike and Whole Foods, on the other hand, offer much more visibility and the opportunity to invest in high-quality businesses supported by strong secular tailwinds. They don't have the same kind of explosive potential as small biotech companies, but they provide quality and reliability instead.
Andrés Cardenal has no position in any stocks mentioned. The Motley Fool recommends Nike and Whole Foods Market. The Motley Fool owns shares of Nike and Whole Foods Market. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.